The information on this page is intended for journalists, press and media. Click YES to get to the newsroom. If you click NO you will come back to Mynewsdesk.com.
Recombinant Antibodies: Covagen AG presents the Fynomer technology
LocationThe Crowne Plaza Berlin City Centre, Germany
Speaker: Dr. Simon Brack, Head of Lead Discovery, Covagen AG, Zürich, Switzerland
Topic: Fynomers Neutralizing IL-17A: Making Use of Fc fusion protein
We will present the versatility and broad applicability of the Fynomer technology. As an example, the isolation and characterization of high-affinity Fynomers capable of neutralizing IL-17 will be shown. Furthermore, engineered Fynomer-Fc fusion proteins having appropriate physico-chemical and in vivo half-life properties are attractive drug candidates for pre-clinical and clinical development.
For more info about the event please visit www.informaglobalevents.com/event/antibodies